Time BioVentures

Time BioVentures is an early-stage venture capital firm based in Los Angeles, California, established in 2020. The firm specializes in investing in the life sciences and healthcare sectors, with a particular emphasis on therapeutics, diagnostics, research tools, and innovations in healthcare delivery. As a Registered Investment Adviser, Time BioVentures aims to support the development of breakthrough technologies and solutions that can enhance patient care and improve health outcomes.

Ryan Moriarty

Senior Associate

Timothy Wright

General Partner

D.A. Wallach

Co-Founder and General Partner

10 past transactions

Phantom Neuro

Series A in 2025
Phantom Neuro is a neurotechnology company focused on developing innovative muscle-machine interfaces to enhance robotic limb rehabilitation. By integrating neurotechnology with robotic systems, Phantom Neuro aims to improve mobility for users through precise control of robotic limbs, facilitating more natural movement and enhancing user experiences. The company employs a minimally invasive approach, which allows for effective rehabilitation solutions that address the needs of individuals with mobility challenges. Additionally, Phantom Neuro explores various applications of its technologies within the broader field of assistive robotics, striving to provide valuable tools that help patients with limb deficits regain control over their lives and improve their overall quality of life.

Conceivable Life Sciences

Series A in 2025
Conceivable Life Sciences is focused on revolutionizing in vitro fertilization (IVF) by developing the first fully automated IVF laboratory. The company employs advanced technologies, including single-cell robotics, to streamline the IVF process, making it more efficient and accessible to individuals and couples aspiring to become parents. By automating key aspects of IVF, Conceivable Life Sciences aims to democratize access to these reproductive technologies, ultimately helping more people fulfill their dreams of parenthood.

Rivermark Medical

Series C in 2024
Rivermark Medical specializes in the development of minimally invasive treatments for Benign Prostatic Hyperplasia (BPH), a condition that affects urinary function in men. The company focuses on device therapies designed to effectively alleviate BPH symptoms with minimal side effects, ensuring a swift recovery for patients. Developed by urologists, Rivermark's innovative approach allows for procedures that require little to no downtime and eliminate the need for post-procedural catheters, enabling patients to quickly resume their normal daily activities.

Brightside Health

Series C in 2024
Brightside Health, Inc. is a telemedicine platform that specializes in providing evidence-based treatments for anxiety and depression. Founded in 2017 and based in San Francisco, California, the company has developed a mobile application that offers personalized mental health care through video visits, messaging, and medication delivery. Its platform enables users to evaluate their mental health, access treatment and support, and communicate with healthcare providers for consultations and ongoing care. Brightside Health utilizes a care model that combines precision psychiatry with continuous monitoring, ensuring members receive effective treatment tailored to their needs. The company’s mission is to help individuals manage their mental health, leading to healthier and more productive lives.

Commons Clinic

Series A in 2023
Commons Clinic is a multi-specialty healthcare facility located in Austin, Texas, founded in 2021. The clinic aims to deliver seamless healthcare treatment by coordinating elite physicians and providing ambulatory services. It offers comprehensive specialty and surgical care programs focusing on pain management, orthopedics, women's health, and men's health. By emphasizing efficient and improved medical care, Commons Clinic strives to enhance the overall patient experience and health outcomes.

BillionToOne

Series C in 2022
BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

Phantom Neuro

Seed Round in 2022
Phantom Neuro is a neurotechnology company focused on developing innovative muscle-machine interfaces to enhance robotic limb rehabilitation. By integrating neurotechnology with robotic systems, Phantom Neuro aims to improve mobility for users through precise control of robotic limbs, facilitating more natural movement and enhancing user experiences. The company employs a minimally invasive approach, which allows for effective rehabilitation solutions that address the needs of individuals with mobility challenges. Additionally, Phantom Neuro explores various applications of its technologies within the broader field of assistive robotics, striving to provide valuable tools that help patients with limb deficits regain control over their lives and improve their overall quality of life.

BillionToOne

Series C in 2022
BillionToOne Inc. is a precision diagnostics company based in Menlo Park, California, that specializes in molecular testing for prenatal and oncology applications. Established in 2016, the company has developed a patented molecular counter platform capable of detecting and quantifying DNA molecules at an extraordinarily precise level. BillionToOne's flagship product, UNITY, is a noninvasive prenatal screening test that analyzes fetal cell-free DNA from a simple blood sample taken from the mother, allowing for the detection of single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and beta-thalassemia. This innovative approach aims to replace more invasive procedures like amniocentesis, providing a safer and more affordable alternative for expecting mothers, particularly in developing countries. Additionally, the company is focused on oncology, offering tests that can accurately identify actionable mutations and assess tumor burden through blood samples.

NanoMosaic

Series A in 2021
NanoMosaic specializes in developing innovative solutions for early illness detection, prognostic monitoring, and biomarker identification. The company utilizes a unique nanoneedle proteomic platform that facilitates protein detection and quantification on a single chip. This technology enhances the capabilities of the medical and healthcare industry by accelerating the discovery and validation of biomarkers, thereby improving early disease detection and monitoring. Through its advanced proteomic system, NanoMosaic aims to contribute significantly to advancements in medical diagnostics and patient care.

DeepSight

Series A in 2021
DeepSight Technology is a health technology company focused on advancing diagnostic medical imaging. By leveraging proprietary sensing technology, the firm combines patented hardware, software, and artificial intelligence to significantly enhance image quality and increase the depth penetration of medical ultrasounds. This innovation aims to make diagnostic imaging safer, faster, more affordable, and more accessible, ultimately benefiting public health and well-being. DeepSight's advancements enable healthcare enterprises to utilize enhanced ultrasound capabilities, which can lead to improved diagnostic outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.